Skip to main content
Duke University Libraries
DukeSpace Scholarship by Duke Authors
  • Login
  • Ask
  • Menu
  • Login
  • Ask a Librarian
  • Search & Find
  • Using the Library
  • Research Support
  • Course Support
  • Libraries
  • About
View Item 
  •   DukeSpace
  • Duke Scholarly Works
  • Scholarly Articles
  • View Item
  •   DukeSpace
  • Duke Scholarly Works
  • Scholarly Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Thumbnail
View / Download
434.2 Kb
Date
2018-12
Authors
Black, Kevin J
Nasrallah, Henry
Isaacson, Stuart
Stacy, Mark
Pahwa, Rajesh
Adler, Charles H
Alva, Gustavo
Cooney, Jeffrey W
Kremens, Daniel
Menza, Matthew A
Meyer, Jonathan M
Patkar, Ashwin A
Simuni, Tanya
Morrissette, Debbi A
Stahl, Stephen M
Show More
(15 total)
Repository Usage Stats
70
views
160
downloads
Abstract
Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP. How best to implement a switch to pimavanserin has not been clear, as there are no controlled trials or case series in the literature to provide guidance. An abrupt switch may interrupt partially effective treatment or potentially trigger rebound effects from antipsychotic withdrawal, whereas cross-taper involves potential drug interactions. A panel of experts drew from published data, their experience treating PDP, lessons from switching antipsychotic drugs in other populations, and the pharmacology of the relevant drugs, to establish consensus recommendations. The panel concluded that patients with PDP can be safely and effectively switched from atypical antipsychotics used off label in PDP to the recently approved pimavanserin by considering each agent's pharmacokinetics and pharmacodynamics, receptor interactions, and the clinical reason for switching (efficacy or adverse events). Final recommendations are that such a switch should aim to maintain adequate 5-HT2A antagonism during the switch, thus providing a stable transition so that efficacy is maintained. Specifically, the consensus recommendation is to add pimavanserin at the full recommended daily dose (34 mg) for 2-6 weeks in most patients before beginning to taper and discontinue quetiapine or clozapine over several days to weeks. Further details are provided for this recommendation, as well as for special clinical circumstances where switching may need to proceed more rapidly.
Type
Journal article
Subject
Humans
Parkinson Disease
Urea
Piperidines
Antiparkinson Agents
Antipsychotic Agents
Consensus
Psychotic Disorders
Practice Guidelines as Topic
Off-Label Use
Drug Substitution
Serotonin 5-HT2 Receptor Antagonists
Permalink
https://hdl.handle.net/10161/21261
Published Version (Please cite this version)
10.1017/s1092852918001359
Publication Info
Black, Kevin J; Nasrallah, Henry; Isaacson, Stuart; Stacy, Mark; Pahwa, Rajesh; Adler, Charles H; ... Stahl, Stephen M (2018). Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS spectrums, 23(6). pp. 402-413. 10.1017/s1092852918001359. Retrieved from https://hdl.handle.net/10161/21261.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
  • Scholarly Articles
More Info
Show full item record

Scholars@Duke

Cooney

Jeffrey W Cooney

Assistant Professor of Neurology
I see patients with a broad range of movement disorders, including Parkinson's disease, tremors, ataxia, dystonia, tics, and Huntington's disease. I employ deep brain stimulation (DBS) therapy for selected patients with Parkinson's disease, tremor, or dystonia, and use botulinum toxin injections for certain patients with dystonia, tremors, or tics. I work with an interdisciplinary team of physicians, therapists, and other healthcare providers, with the overall goal of helping to improve the live
Patkar

Ashwin Anand Patkar

Professor of Psychiatry and Behavioral Sciences

Mark Allen Stacy

Professor of Neurology
Mark Stacy has clinical trial efforts concentrated on Neuroprotective and Neuro-regenerative therapies in PD, and developing biomarkers for early diagnosis in PD. He has extensive experience with Glial Derived Neurotrophic Factor (GDNF), neuroimmunophyllins (GPI-1046, AMG-474), jnk inhibitors (CEP-1347, TCH-346), and viral vectors (Ceregene). His independent research interests in Parkinson’s disease include motor and non-motor symptoms of wearing off, and pathological gambling and oth
This author no longer has a Scholars@Duke profile, so the information shown here reflects their Duke status at the time this item was deposited.
Alphabetical list of authors with Scholars@Duke profiles.
Open Access

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy

Rights for Collection: Scholarly Articles


Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info

Make Your Work Available Here

How to Deposit

Browse

All of DukeSpaceCommunities & CollectionsAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit DateThis CollectionAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit Date

My Account

LoginRegister

Statistics

View Usage Statistics
Duke University Libraries

Contact Us

411 Chapel Drive
Durham, NC 27708
(919) 660-5870
Perkins Library Service Desk

Digital Repositories at Duke

  • Report a problem with the repositories
  • About digital repositories at Duke
  • Accessibility Policy
  • Deaccession and DMCA Takedown Policy

TwitterFacebookYouTubeFlickrInstagramBlogs

Sign Up for Our Newsletter
  • Re-use & Attribution / Privacy
  • Harmful Language Statement
  • Support the Libraries
Duke University